PKTX Stock Overview
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs).
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
ProtoKinetix, Incorporated Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.015 |
52 Week High | US$0.035 |
52 Week Low | US$0.01 |
Beta | -0.11 |
1 Month Change | -26.50% |
3 Month Change | -24.23% |
1 Year Change | -46.55% |
3 Year Change | -92.83% |
5 Year Change | -80.96% |
Change since IPO | 267.50% |
Recent News & Updates
Recent updates
Shareholder Returns
PKTX | US Biotechs | US Market | |
---|---|---|---|
7D | -26.1% | -0.5% | 0.6% |
1Y | -46.5% | 9.6% | 29.5% |
Return vs Industry: PKTX underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: PKTX underperformed the US Market which returned 29.5% over the past year.
Price Volatility
PKTX volatility | |
---|---|
PKTX Average Weekly Movement | 28.4% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PKTX's share price has been volatile over the past 3 months.
Volatility Over Time: PKTX's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | n/a | Clarence Smith | https://www.protokinetix.com |
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company’s AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases.
ProtoKinetix, Incorporated Fundamentals Summary
PKTX fundamental statistics | |
---|---|
Market cap | US$5.10m |
Earnings (TTM) | -US$886.66k |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.7x
P/E RatioIs PKTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PKTX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$886.66k |
Earnings | -US$886.66k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0026 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did PKTX perform over the long term?
See historical performance and comparison